14C-BIRB 796 BS
Drug14C-radiolabeled BIRB 796 BS
NCT Number: NCT02211885
Study to characterize the pharmacokinetics of 14C-radiolabeled BIRB 796 BS and its metabolites including excretion and mass balance of parent compound and radioactivity; to isolate, identify and quantify major radiolabeled metabolites of BIRB 796 in plasma, urine and feces
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
14C-radiolabeled BIRB 796 BS
Time frame: up to 5 days
Time frame: up to 5 days
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 5 days
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 96 hours after drug administration
Time frame: up to 5 days
Time frame: up to 5 days
Time frame: up to 96 hours after drug administration
Time frame: up to 24 hours after drug administration
Time frame: up to 48 hours after drug administration
Boehringer Ingelheim
Industry
A Phase I Single Oral Dose (100 mg) Trial to Characterize the Excretion Balance of 14c-radiolabeled BIRB 796 BS and to Determine Its Metabolites in Normal Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details